Homologous recombination pathway alterations in basal-like breast cancer - Takeaways - MDSpire

Homologous recombination pathway alterations in basal-like breast cancer

  • By

  • Simon Aho

  • Boris Guyot

  • Véronique Maguer-Satta

  • June 18, 2026

  • 0 min

Share

  • 1

    Basal-like breast carcinoma (BLBC) accounts for 15-20% of breast cancer cases and is linked to poor prognosis.

  • 2

    BLBC shares characteristics with BRCA1-deficient tumors, suggesting potential alterations in homologous recombination (HR) DNA repair.

  • 3

    Homologous recombination deficiency (HRD) may be enriched in BLBC, but its clinical implications remain incompletely defined.

  • 4

    Current HRD detection methods have limitations, and most studies derive from triple-negative breast cancer cohorts rather than BLBC.

  • 5

    Future studies focused on molecularly defined cohorts are needed to clarify the diagnostic and therapeutic value of HRD in BLBC.

Original Source(s)

Homologous recombination pathway alterations in basal-like breast cancer

  • by Simon Aho, Boris Guyot, Véronique Maguer-Satta

  • June 18, 2026

Related Content

Optical coherence tomography features and visual prognosis in vitreoretinal lymphoma: a structured phenotyping study

Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database

Hepatic metastasis of mucinous adenocarcinoma with neuroendocrine differentiation harboring a rare HER2 R678Q mutation: a case report and literature review